DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
...ry angioedema (HAE). A webcast presentation of the edema3 data is scheduled for Tuesday, April 17, 2007 at 1...or both the primary and secondary endpoints in the edema3 trial. The primary endpoint, symptom improvement...There were no drug-related serious adverse events. edema3 is the largest successfully completed, placebo-con...Dyax Corp.'s DX-88 for Hereditary Angioedema Meets Primary and ...
A webcast presentation of the EDEMA3 data is scheduled for Tuesday, April 17, ... EDEMA3 is the largest successfully completed, placebo-controlled trial for this ...Ecallantide (Kalbitor) Advisory Committee Briefing Document
Treated with Ecallantide for Episodes 2 Through 6 in EDEMA3-RD ... 59 ... Table 37. Summary of Efficacy Results for EDEMA3-DB: ITT-as-Randomized. Population ...Press Release: DX-88 for Hereditary Angioedema Meets Primary and ...
Press Release: DX-88 for Hereditary Angioedema Meets Primary and Secondary ... EDEMA3 is the largest successfully completed, placebo-controlled trial for this ...Dyax: Hereditary Angioedema (HAE)
Dyax Corp Clinical Trials, Cambridge, Massachusetts ... EDEMA3, a 72-patient, multicenter, Phase 3, placebo-controlled trial was ...